Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …

In recent years, our understanding of the molecular pathogenesis of myeloid neoplasms,
including acute myeloid leukemia (AML), has been greatly advanced by genomics discovery …

RUNX1 is a member of the core-binding factor family of transcription factors and is
indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is …

Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

The clinical and prognostic relevance of many recently identified driver gene mutations in
adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …